Amneal to Acquire Kashiv BioSciences for $750M Upfront, Unveils Strong Q1 Preliminary Results
AMRX sits 83% above its 52-week low of $7.02.
Summary
Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences for $750 million upfront, aiming to become a global biosimilar leader, and reported strong preliminary Q1 2026 financial results.
Key Events · M&A and Partnerships · AMRX
-
Acquisition Agreement
Amneal will acquire Kashiv BioSciences for $750 million upfront ($375M cash, $375M equity), plus up to $350 million in potential milestone payments and royalties.
-
Strategic Expansion
The acquisition is expected to create a global biosimilar leader, adding a robust R&D and manufacturing platform and diversifying Amneal's growth into the 2030s.
-
Equity Dilution
The equity component of the upfront consideration represents approximately 8% dilution, with about 29 million new shares.
-
Strong Q1 Preliminary Results
Reported preliminary Q1 2026 net revenue of $723 million (+4%), adjusted EBITDA of $202 million (+19%), and adjusted EPS of $0.27 (+29%).
Analysis · AMRX · Life Sciences
This DEFA14A filing details Amneal's strategic acquisition of Kashiv BioSciences, a move designed to establish the company as a global leader in biosimilars and extend its growth profile into the 2030s. The upfront consideration of $750 million, comprising $375 million in cash and $375 million in equity (resulting in approximately 8% dilution), represents a significant investment. The company anticipates substantial financial synergies of $400M-$500M over time and expects minimal long-term impact on leverage ratios. Concurrently, Amneal reported robust preliminary Q1 2026 results, with net revenue up 4%, adjusted EBITDA up 19%, and adjusted EPS up 29%, indicating strong operational performance as it embarks on this transformational acquisition. The acquisition is subject to shareholder approval.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMRX was trading at $12.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $7.02 to $15.42. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.